If you made any changes in Pure, your changes will be visible here soon.

Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.

  • 6 Similar Profiles
Lung Neoplasms Medicine & Life Sciences
Lung Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Hepatocyte Growth Factor Medicine & Life Sciences
Bombesin Receptors Medicine & Life Sciences
Epithelial Cells Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2024

Research Output 1981 2019

1 Citation (Scopus)

Lung adenocarcinoma syndecan-2 potentiates cell invasiveness

Tsoyi, K., Osorio, J. C., Chu, S. G., Fernandez, I. E., De Frias, S. P., Sholl, L., Cui, Y., Tellez, C. S., Siegfried, J. M., Belinsky, S. A., Perrella, M. A., El-Chemaly, S. & Rosas, I. O., Jun 1 2019, In : American journal of respiratory cell and molecular biology. 60, 6, p. 659-666 8 p.

Research output: Contribution to journalArticle

Syndecan-2
Syntenins
Tumors
Adenocarcinoma of lung
Neoplasm Metastasis
3 Citations (Scopus)

Gene promoter hypermethylation detected in sputum predicts FEV1 decline and all-cause mortality in smokers

Leng, S., Diergaarde, B., Picchi, M. A., Wilson, D. O., Gilliland, F. D., Yuan, J. M., Siegfried, J. M. & Belinsky, S. A., Jul 15 2018, In : American journal of respiratory and critical care medicine. 198, 2, p. 187-196 10 p.

Research output: Contribution to journalArticle

Open Access
Sputum
Lung Neoplasms
Methylation
Mortality
Genes
1 Citation (Scopus)

Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer

Stabile, L. P., Farooqui, M., Kanterewicz, B., Abberbock, S., Kurland, B. F., Diergaarde, B. & Siegfried, J. M., Mar 1 2018, In : Journal of Thoracic Oncology. 13, 3, p. 399-412 14 p.

Research output: Contribution to journalArticle

Aromatase Inhibitors
Non-Steroidal Anti-Inflammatory Agents
Tobacco
Lung Neoplasms
Lung

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

Garon, E. B., Siegfried, J. M., Stabile, L. P., Young, P. A., Marquez-Garban, D. C., Park, D. J., Patel, R., Hu, E. H., Sadeghi, S., Parikh, R. J., Reckamp, K. L., Adams, B., Elashoff, R. M., Elashoff, D., Grogan, T., Wang, H. J., Dacic, S., Brennan, M., Valdes, Y., Davenport, S. & 4 othersDubinett, S. M., Press, M. F., Slamon, D. J. & Pietras, R. J., Sep 1 2018, In : Lung Cancer. 123, p. 91-98 8 p.

Research output: Contribution to journalArticle

Open Access
Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Disease-Free Survival
Survival
fulvestrant
3 Citations (Scopus)

STAT3 cyclic decoy demonstrates robust antitumor effects in non–small cell lung cancer

Njatcha, C., Farooqui, M., Kornberg, A., Johnson, D. E., Grandis, J. R. & Siegfried, J. M., Sep 1 2018, In : Molecular Cancer Therapeutics. 17, 9, p. 1917-1926 10 p.

Research output: Contribution to journalArticle

Non-Small Cell Lung Carcinoma
STAT3 Transcription Factor
Carcinoma
Lung
Oligonucleotides